Literature DB >> 15867379

Valproic acid alters chromatin structure by regulation of chromatin modulation proteins.

Douglas C Marchion1, Elona Bicaku, Adil I Daud, Daniel M Sullivan, Pamela N Munster.   

Abstract

Histone acetylation and deacetylation are crucial in the regulation of gene expression. Dynamic changes in gene expression may affect chromatin structure and, consequently, the interaction of chromatin with regulatory factors. In this study, the effects of the antiseizure drug valproic acid (VPA) on the expression of genes that regulate the structure of chromatin and the access of macromolecules to the DNA were investigated. Exposure of breast cancer cells to VPA resulted in rapid dose-dependent hyperacetylation of the histones H3 and H4. VPA further induced a depletion of several members of the structural maintenance of chromatin (SMC) proteins, SMC-associated proteins, DNA methyltransferase, and heterochromatin proteins. Down-regulation of these proteins was associated with chromatin decondensation. The observed alterations of chromatin structure correlated with enhanced sensitivity of DNA to nucleases and increased interaction of DNA with intercalating agents. VPA-induced chromatin decondensation led to a sequence-specific potentiation of DNA-damaging agents in cell culture and xenograft models. Modulation of heterochromatin maintenance proteins was not a direct, but a downstream, effect of histone acetylation. The effects on the chromatin structure were reversible upon drug withdrawal, but obligatory for the potentiation of DNA-damaging agents. In addition to their antitumor activity as single agents, the chromatin decondensation induced by histone deacetylase inhibitors may enhance the efficacy of cytotoxic agents that act by targeting DNA. The proposed mechanism of action suggests an effect of drug sequencing on the antitumor activity of these drugs.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15867379     DOI: 10.1158/0008-5472.CAN-04-2478

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  73 in total

1.  HDAC5 is required for maintenance of pericentric heterochromatin, and controls cell-cycle progression and survival of human cancer cells.

Authors:  P Peixoto; V Castronovo; N Matheus; C Polese; O Peulen; A Gonzalez; M Boxus; E Verdin; M Thiry; F Dequiedt; D Mottet
Journal:  Cell Death Differ       Date:  2012-02-03       Impact factor: 15.828

Review 2.  Epigenetically regulated imprinted genes and foetal programming.

Authors:  Eric B Keverne
Journal:  Neurotox Res       Date:  2010-03-23       Impact factor: 3.911

3.  Fractal Characterization of Chromatin Decompaction in Live Cells.

Authors:  Ji Yi; Yolanda Stypula-Cyrus; Catherine S Blaha; Hemant K Roy; Vadim Backman
Journal:  Biophys J       Date:  2015-12-01       Impact factor: 4.033

4.  c-Myc and Sp1 contribute to proviral latency by recruiting histone deacetylase 1 to the human immunodeficiency virus type 1 promoter.

Authors:  Guochun Jiang; Amy Espeseth; Daria J Hazuda; David M Margolis
Journal:  J Virol       Date:  2007-08-01       Impact factor: 5.103

5.  Valproic acid suppresses Nrf2/Keap1 dependent antioxidant protection through induction of endoplasmic reticulum stress and Keap1 promoter DNA demethylation in human lens epithelial cells.

Authors:  Periyasamy Palsamy; Keshore R Bidasee; Toshimichi Shinohara
Journal:  Exp Eye Res       Date:  2014-02-10       Impact factor: 3.467

6.  Role of histone deacetylase inhibitor-induced reactive oxygen species and DNA damage in LAQ-824/fludarabine antileukemic interactions.

Authors:  Roberto R Rosato; Jorge A Almenara; Sonia C Maggio; Stefanie Coe; Peter Atadja; Paul Dent; Steven Grant
Journal:  Mol Cancer Ther       Date:  2008-10       Impact factor: 6.261

7.  Valproate in combination with rituximab and CHOP as first-line therapy in diffuse large B-cell lymphoma (VALFRID).

Authors:  Kristina Drott; Hans Hagberg; Karin Papworth; Thomas Relander; Mats Jerkeman
Journal:  Blood Adv       Date:  2018-06-26

8.  Effects of mood stabilizers on DNA damage in an animal model of mania.

Authors:  Ana Cristina Andreazza; Marcia Kauer-Sant'Anna; Benicio N Frey; Laura Stertz; Caroline Zanotto; Leticia Ribeiro; Karine Giasson; Samira S Valvassori; Gislaine Z Réus; Mirian Salvador; João Quevedo; Carlos A Gonçalves; Flavio Kapczinski
Journal:  J Psychiatry Neurosci       Date:  2008-11       Impact factor: 6.186

9.  Histone deacetylase inhibitors valproate and trichostatin A are toxic to neuroblastoma cells and modulate cytochrome P450 1A1, 1B1 and 3A4 expression in these cells.

Authors:  Jana Hřebačková; Jitka Poljaková; Tomáš Eckschlager; Jan Hraběta; Pavel Procházka; Svatopluk Smutný; Marie Stiborová
Journal:  Interdiscip Toxicol       Date:  2009-09-28

10.  Phase I trial of vorinostat and doxorubicin in solid tumours: histone deacetylase 2 expression as a predictive marker.

Authors:  P N Munster; D Marchion; S Thomas; M Egorin; S Minton; G Springett; J-H Lee; G Simon; A Chiappori; D Sullivan; A Daud
Journal:  Br J Cancer       Date:  2009-09-08       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.